Company intelligence / Profile preview

Omeros Corporation

Seattle, Washington, United Statesomeros.com ↗

Ownership: Public · OMER
Employees: ~200
Development stage: Phase 3

Overview

Omeros has developed multiple clinical-stage programs including narsoplimab for complement-mediated diseases. The company previously commercialized OMIDRIA, which was divested in 2021 for over $1 billion. Current pipeline includes multiple first-in-class drugs targeting complement system and CNS disorders.

Therapeutic areas: PsychiatryNephrologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: Small-molecule therapeuticsProtein therapeuticsAntibody therapeutics
Industry: Biotech

Drug pipeline

12 assets

narsoplimab

Approved

11 more assets in the full pipeline.

Request access →

Partnerships

National Institute on Drug Abuse (NIDA)National Institutes of Health (NIH)

Financials

Market cap: $1.3B
Total revenue: $28.5M
Enterprise value: $1.3B

Beyond the preview

Go deeper on Omeros Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omeros Corporation.

Explore the full profile